{"entity":{"id":"coherus","kind":"company","name":"Coherus BioSciences","aka":["Coherus BioSciences, Inc.","Coherus Oncology"],"tldr":"Coherus is a Californian company that grew up on biosimilars and now holds the US rights to toripalimab, the anti-PD-1 antibody approved in 2023 for nasopharyngeal carcinoma, the first FDA approval for that cancer.","summary":"Coherus BioSciences, based in Redwood City, California, built its business on biosimilars of pegfilgrastim and other biologics before refocusing on oncology. It licensed the anti-PD-1 antibody toripalimab from Junshi Biosciences for the United States and Canada and won FDA approval in October 2023 for recurrent or metastatic nasopharyngeal carcinoma with chemotherapy, the first drug approved in the United States for that disease. The company is developing toripalimab combinations and other immuno-oncology candidates. Company facts are from the official website and FDA approval records.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.coherus.com/"},{"label":"FDA: oncology and hematologic malignancies approval notifications","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications"}],"tags":["fda-oce-applicant"],"related":[],"cancers":["head-and-neck","esophageal"],"sections":["immunotherapy"],"technologies":[],"targets":[],"drugs":["toripalimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06975293"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Redwood City, CA","country":"US","companyType":"biotech","website":"https://www.coherus.com/","stage":"public","investors":[],"funding":[]},"route":"/companies/coherus/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"drug":[{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/"}],"trial":[{"id":"nct07281716","kind":"trial","name":"Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC","route":"/trials/nct07281716/"},{"id":"nct07140679","kind":"trial","name":"Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer","route":"/trials/nct07140679/"},{"id":"jupiter-02","kind":"trial","name":"JUPITER-02","route":"/trials/jupiter-02/"},{"id":"nct07277322","kind":"trial","name":"Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases","route":"/trials/nct07277322/"},{"id":"nct06975293","kind":"trial","name":"STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas","route":"/trials/nct06975293/"}]}}